Momoi T, Yamanaka C, Tanaka R, Yoshida A, Okumura M, Yamakura S, Takasaki Y, Sasaki H, Kawai M
Department of Paediatrics, Wakayama Red Cross Hospital, Japan.
Eur J Pediatr. 1995 Nov;154(11):886-9. doi: 10.1007/BF01957498.
Serum creatinine phosphokinase (s-CPK) increased to more than 500 U/l in 5 out of 21 patients with growth hormone (GH) deficiency during the 2 years of treatment with biosynthetic GH. In three of these five patients, s-CPK had elevated gradually after the start of GH treatment and remained high in one patient except in the period when GH injection was interrupted, and gradually decreased in the other two patients during treatment. These three patients had complete GH deficiency associated with multiple pituitary hormone deficiency due to pituitary stalk transection. One of the remaining two patients had Noonan syndrome and his s-CPK levels before therapy were relatively high. The fifth patient was a baseball athlete and the elevation of s-CPK seemed to be attributable to the strenuous exercise. Conclusion. s-CPK increases significantly in a certain group of patients with GH deficiency during GH replacement therapy. Measurement of s-CPK is to be included in the follow up laboratory tests at least in the 1st treatment year to evaluate the potential hazardous effects of GH on muscle.
在21例生长激素（GH）缺乏患者接受生物合成GH治疗的2年期间，21例中有5例血清肌酸磷酸激酶（s-CPK）升高至500 U/l以上。在这5例患者中，有3例在开始GH治疗后s-CPK逐渐升高，其中1例患者除了中断GH注射期间外一直保持高水平，另外2例患者在治疗期间s-CPK逐渐下降。这3例患者因垂体柄横断导致完全性GH缺乏并伴有多种垂体激素缺乏。其余2例患者中，1例患有努南综合征，其治疗前s-CPK水平相对较高。第5例患者是一名棒球运动员，s-CPK升高似乎归因于剧烈运动。结论。在一组GH缺乏患者接受GH替代治疗期间，s-CPK显著升高。至少在治疗的第1年，s-CPK的检测应纳入随访实验室检查，以评估GH对肌肉的潜在有害影响。
